tiprankstipranks
Trending News
More News >
P3 Health Partners (PIII)
NASDAQ:PIII
US Market

P3 Health Partners (PIII) Price & Analysis

Compare
113 Followers

PIII Stock Chart & Stats

$3.50
-$0.01(-4.21%)
At close: 4:00 PM EST
$3.50
-$0.01(-4.21%)

Bulls Say, Bears Say

Bulls Say
EBITDA Expansion TargetsManagement's pursuit of $120 million to $170 million in EBITDA expansion opportunities indicates clear targets for profit growth if execution stays on track.
Operational ImprovementsManagement highlighted the operational improvement plan is embedded and has produced over $100 million in EBITDA improvement, supporting ongoing margin recovery.
Risk Adjustment And Clinical ScalingFocused initiatives in risk coding, clinical program scaling, and contract enhancements could increase reimbursement capture and operational leverage, contributing to EBITDA growth.
Bears Say
Margin PressurePersistent margin pressure and remaining earnings challenges suggest profitability may stay under strain despite some operational gains.
Revenue ShortfallRevenue weakness in the first half of the year points to top-line challenges that could constrain cash flow and investor confidence until growth stabilizes.
Unfavorable Settlements And AdjustmentsUnfavorable mid-year settlements and intra-year adjustments that widened adjusted EBITDA losses create uncertainty about near-term earnings and forecasting.

P3 Health Partners News

PIII FAQ

What was P3 Health Partners’s price range in the past 12 months?
P3 Health Partners lowest stock price was $1.52 and its highest was $11.30 in the past 12 months.
    What is P3 Health Partners’s market cap?
    P3 Health Partners’s market cap is $19.02M.
      When is P3 Health Partners’s upcoming earnings report date?
      P3 Health Partners’s upcoming earnings report date is Mar 26, 2026 which is in 21 days.
        How were P3 Health Partners’s earnings last quarter?
        P3 Health Partners released its earnings results on Nov 13, 2025. The company reported -$9.67 earnings per share for the quarter, missing the consensus estimate of -$5.292 by -$4.378.
          Is P3 Health Partners overvalued?
          According to Wall Street analysts P3 Health Partners’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does P3 Health Partners pay dividends?
            P3 Health Partners does not currently pay dividends.
            What is P3 Health Partners’s EPS estimate?
            P3 Health Partners’s EPS estimate is -8.06.
              How many shares outstanding does P3 Health Partners have?
              P3 Health Partners has 3,286,465 shares outstanding.
                What happened to P3 Health Partners’s price movement after its last earnings report?
                P3 Health Partners reported an EPS of -$9.67 in its last earnings report, missing expectations of -$5.292. Following the earnings report the stock price went down -2.286%.
                  Which hedge fund is a major shareholder of P3 Health Partners?
                  Currently, no hedge funds are holding shares in PIII
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    P3 Health Partners

                    P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.

                    P3 Health Partners (PIII) Earnings & Revenues

                    PIII Earnings Call

                    Q3 2025
                    0:00 / 0:00
                    Earnings Call Sentiment|Neutral
                    The earnings call highlighted several positive developments, including increased capitated revenue, successful operational improvements, strategic ventures, and reduced operating expenses. However, these are counterbalanced by significant adjusted EBITDA losses and revised financial guidance, indicating ongoing financial challenges.View all PIII earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Pennant Group
                    Oncology Institute
                    DocGo
                    InnovAge Holding
                    Agilon Health
                    Popular Stocks